Abc Pediatrics of Dunn, PA
Abc Pediatrics of Dunn, PA was paid $28.10M by Medicaid between Jan 2018 and Dec 2024, across 116 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 21% of everything it billed.
33Billing provider infoABC PEDIATRICS OF DUNN, PA
DUNN, NC 28334
DUNN, NC 28334
33aNPI1417061011assigned 08/19/2006
33bProvider typeSpecialist
28Total paid$28.10M
24GClaims1,315,568
24DCodes billed116
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in North Carolina
Rank by total paid#1 of 172
Median peer was paid$83K
This provider vs. median340×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 99,655 | $2.89M | |
| 2019 | 97,146 | $2.77M | |
| 2020 | 97,338 | $2.72M | |
| 2021 | 197,762 | $4.38M | |
| 2022 | 300,930 | $6.00M | |
| 2023 | 273,278 | $5.19M | |
| 2024incomplete | 249,459 | $4.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 102,750 | 87,262 | $5.77M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 41,407 | 34,375 | $3.41M |
| 99199 | Unlisted special service, procedure or report | 10% | 488,655 | 286,832 | $2.93M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 8.5% | 18,337 | 14,688 | $2.40M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4.6% | 9,770 | 9,179 | $1.30M |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 3.3% | 3,934 | 1,063 | $940K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.3% | 11,240 | 10,117 | $920K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.2% | 11,589 | 9,780 | $908K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.1% | 13,737 | 12,814 | $866K |
| 99401 | 3.1% | 29,093 | 22,587 | $862K | |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.7% | 12,538 | 9,299 | $747K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2.6% | 20,782 | 18,350 | $735K |
104 more codes
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.6% | 8,787 | $724K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.4% | 36,325 | $672K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.8% | 5,780 | $510K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.7% | 36,228 | $482K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 66,450 | $467K |
| 86328 | 1.3% | 9,852 | $378K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 3,953 | $292K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,397 | $244K |
| 87081 | <1% | 33,532 | $224K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 993 | $220K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,923 | $151K |
| 96112 | <1% | 1,278 | $140K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,301 | $136K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 14,801 | $129K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,195 | $108K |
| 82465 | <1% | 22,237 | $106K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,389 | $103K |
| 87634 | <1% | 2,530 | $73K | |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 2,153 | $69K |
| 95117 | <1% | 7,440 | $69K | |
| 99443 | <1% | 1,095 | $68K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,201 | $61K |
| 90474 | <1% | 3,105 | $60K | |
| 99051 | <1% | 2,126 | $53K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,828 | $49K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,825 | $49K |
| 96127 | <1% | 11,944 | $48K | |
| 92551 | <1% | 23,961 | $47K | |
| 80053 | Comprehensive metabolic panel | <1% | 4,548 | $44K |
| 96160 | <1% | 20,378 | $44K | |
| 90651 | <1% | 1,761 | $40K | |
| 0240U | <1% | 281 | $37K | |
| 81003 | <1% | 22,801 | $35K | |
| 96111 | <1% | 324 | $33K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,726 | $32K |
| D1206 | Topical application of fluoride varnish | <1% | 2,165 | $31K |
| 80305 | <1% | 1,991 | $25K | |
| 83655 | <1% | 1,768 | $23K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,004 | $18K |
| 90837 | Psychotherapy session, about an hour | <1% | 208 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,853 | $15K |
| 0072A | <1% | 240 | $14K | |
| 0002A | <1% | 263 | $14K | |
| 99173 | <1% | 24,450 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,101 | $12K |
| 90734 | <1% | 662 | $11K | |
| 90686 | <1% | 7,293 | $11K | |
| 94664 | <1% | 1,018 | $10K | |
| 0001A | <1% | 329 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 932 | $9K |
| 81001 | <1% | 3,158 | $8K | |
| 0071A | <1% | 144 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 777 | $7K |
| 80061 | Lipid panel | <1% | 471 | $7K |
| E0570 | Nebulizer, with compressor | <1% | 52 | $6K |
| 69210 | <1% | 186 | $6K | |
| 99442 | <1% | 156 | $6K | |
| 90621 | <1% | 330 | $5K | |
| 94150 | <1% | 669 | $5K | |
| 90619 | <1% | 843 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 281 | $5K |
| 98968 | <1% | 195 | $4K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 67 | $3K |
| 94010 | <1% | 165 | $3K | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 783 | $2K |
| 90715 | <1% | 412 | $2K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 24 | $2K |
| A4614 | Peak expiratory flow rate meter, hand held | <1% | 69 | $2K |
| G0312 | Immunization counseling by a physician or other qualified health care professional when the vaccine(s) is not administered on the same date of service for ages under 21, 5 to 15 mins time (this code is used for medicaid billing purposes) | <1% | 42 | $1K |
| 90661 | <1% | 1,196 | $1K | |
| 95115 | <1% | 117 | $793.53 | |
| 94760 | <1% | 7,054 | $740.55 | |
| 90674 | <1% | 812 | $695.29 | |
| 86308 | <1% | 75 | $458.29 | |
| 95012 | <1% | 31 | $443.52 | |
| 90670 | <1% | 5,793 | $400.00 | |
| 36416 | <1% | 62,430 | $274.88 | |
| 90716 | <1% | 1,100 | $264.80 | |
| 96380 | <1% | 16 | $257.10 | |
| 81025 | <1% | 35 | $241.80 | |
| 90671 | <1% | 1,577 | $232.45 | |
| 90633 | <1% | 1,270 | $230.68 | |
| 99402 | <1% | 33 | $118.14 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 22 | $112.80 |
| 90707 | <1% | 1,062 | $74.97 | |
| A4617 | Mouth piece | <1% | 31 | $70.00 |
| 96161 | <1% | 17 | $63.58 | |
| 91300 | <1% | 738 | $28.60 | |
| 90744 | <1% | 1,311 | $26.08 | |
| 99072 | <1% | 17,957 | $0.88 | |
| 90700 | 0% | 984 | $0.00 | |
| 90685 | 0% | 343 | $0.00 | |
| 90713 | 0% | 86 | $0.00 | |
| 3078F | 0% | 64 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 1,345 | $0.00 |
| 90698 | 0% | 4,060 | $0.00 | |
| 99000 | 0% | 7,627 | $0.00 | |
| 90680 | 0% | 3,199 | $0.00 | |
| 91307 | 0% | 475 | $0.00 | |
| 90647 | 0% | 42 | $0.00 | |
| 91305 | 0% | 62 | $0.00 | |
| 3044F | 0% | 102 | $0.00 | |
| 90697 | 0% | 80 | $0.00 | |
| 3074F | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHIODO, VINCENT (OWNER)